Unlearn bblsa metagenomi btp Novotech

Tuesday, June 6

In-person & virtual sessions + livestream

  • 6:00 - 6:50am ET In-person
    Registration & networking breakfast
  • 7:00 - 7:35am ET In-person Livestream
    Fireside chat with Drew Armstrong & Monika Vnuk
  • 7:40 - 8:40am ET In-person Livestream
    How do you do a biotech deal — or keep one — in this economy?
  • 8:50 - 9:20am ET In-person Livestream
    Fireside chat with Arsalan Arif & Charles Fisher
  • 9:30 - 10:25am ET In-person Livestream
    The VCs: What are the biotech creators funding now? And how?
  • 1:00 - 1:55pm ET Virtual
    R&D chiefs are taking a hard look at what’s in the pipeline — and what’s out
  • 2:00 - 2:25pm ET Virtual
    Fireside chat with Drew Armstrong & Andrew Obenshain
  • 6:00 - 8:00pm ET In-person
    Let’s talk biotech funding — over drinks

Wednesday, June 7

virtual sessions

  • 9:00 - 9:25am ET Virtual
    Fireside chat with Drew Armstrong & David Epstein
  • 9:30 - 10:25am ET Virtual
    LGBTQ+ leaders enter the biotech chat
  • 10:30 - 11:30am ET Virtual
    The evolution of clinical trials
  • 1:00 - 1:55pm ET Virtual
    Forging new biotech ties with China
Tuesday, june 6
  • In-Person
  • Livestream

Fireside chat with Drew Armstrong & Monika Vnuk

An in-depth conversation featuring Endpoints Executive Editor Drew Armstrong and Monika Vnuk, Global Head of Business Development and Partnering of Sanofi.

Monika Vnuk

Monika Vnuk

Global Head of Business Development and Partnering

Sanofi
Drew Armstrong

Drew Armstrong

Executive Editor

Endpoints News
Tuesday, june 6
  • In-Person
  • Livestream

How do you do a biotech deal — or keep one — in this economy?

The freeze up on biotech IPOs has put a heavy premium on dealmaking from the biotech side. Collaborations with deep-pocket players offer new revenue sources and the chance to build pipeline. But they can be harder than ever to hold on to. We’re gathering a panel of longtime biotech players to talk about the new rules of the game.

Jeb Keiper

Jeb Keiper

President & Chief Executive Officer

Nimbus Therapeutics
Andy Plump

Andy Plump

President, Research & Development

Takeda
Samarth Kulkarni

Samarth Kulkarni

Chief Executive Officer

CRISPR Therapeutics
Adam M. Koppel

Adam M. Koppel

Partner

Bain Capital Life Sciences
Ronny Gal

Ronny Gal

Chief Strategy and Growth Officer

Novartis
John Carroll

John Carroll

Editor & Founder

Endpoints News
Jonathan P. Gertler

Jonathan P. Gertler

Managing Partner & CEO

Back Bay Life Science Advisors
Tuesday, june 6
  • In-Person
  • Livestream

Fireside chat with Arsalan Arif & Charles Fisher

An in-depth conversation featuring Endpoints Founder & Publisher Arsalan Arif and Charles Fisher, CEO of Unlearn.

Charles Fisher

Charles Fisher

CEO

Unlearn.AI
Arsalan Arif

Arsalan Arif

Founder & Publisher

Endpoints News
Tuesday, june 6
  • In-Person
  • Livestream

The VCs: What are the biotech creators funding now? And how?

Unless you’ve been living under a rock, you’re acutely aware of the change in environment in biotech VC investing. The 1-2 Wall Street dance of A round to S-1 is over, indefinitely, and new biotech creators are digging in for the long haul. Where do they get their startup ideas now and who gets a green light on funding? We’ll get into it in depth with our panel of veteran biotech investors as the 3.0 generation takes shapes.

Geoffrey von Maltzahn

Geoffrey von Maltzahn

General Partner

Flagship Pioneering
Alaa Halawa

Alaa Halawa

Executive Director & Co-Head of U.S. Ventures

Mubadala Capital
Brian Goodman

Brian Goodman

General Partner

MPM Capital
Alexandra Cantley

Alexandra Cantley

Partner

Polaris Partners
John Carroll

John Carroll

Editor & Founder

Endpoints News
Tuesday, june 6
  • virtual

R&D chiefs are taking a hard look at what’s in the pipeline — and what’s out

Continuing our theme of the week, we’re talking to a group of pharma R&D chiefs about the way they are picking and choosing which drugs to push ahead. There’s a rising bar on what qualifies as “positive,” as well as a keen interest in what can move the commercial dial once it is approved. Getting lost in translation? Listen in.

John Reed

John Reed

Executive Vice President, Pharmaceuticals, R&D

Johnson & Johnson
Shreeram Aradhye

Shreeram Aradhye

President, Global Drug Development & Chief Medical Officer

Novartis
Menelas N. Pangalos

Menelas N. Pangalos

EVP & President BioPharmaceuticals R&D

AstraZeneca
David M. Reese

David M. Reese

Executive Vice President, Research and Development

Amgen
Priya Singhal

Priya Singhal

Executive Vice President, Head of Development

Biogen
John Carroll

John Carroll

Editor & Founder

Endpoints News
Tuesday, june 6
  • virtual

Fireside chat with Drew Armstrong & Andrew Obenshain

An in-depth conversation featuring Endpoints Executive Editor Drew Armstrong and Andrew Obenshain, Chief Executive Officer of bluebird bio.

Andrew Obenshain

Andrew Obenshain

Chief Executive Officer

bluebird bio
Drew Armstrong

Drew Armstrong

Executive Editor

Endpoints News
Tuesday, june 6
  • In-Person

Let’s talk biotech funding — over drinks

Join John Carroll in a fireside chat discussing the funding scene in biotech with Katherine Andersen, Head of Life Science & Healthcare at HSBC. Close out the day with networking, premium open bar, and dinner bites.

Katherine Andersen

Katherine Andersen

Head of Life Science & Healthcare, Commercial Banking

HSBC Bank USA, National Association
John Carroll

John Carroll

Editor & Founder

Endpoints News
Wednesday, june 7
  • virtual

Fireside chat with Drew Armstrong & David Epstein

In-depth conversation featuring Endpoints Executive Editor Drew Armstrong and David Epstein, CEO of Seagen.

David Epstein

David Epstein

Chief Executive Officer

Seagen
Drew Armstrong

Drew Armstrong

Executive Editor

Endpoints News
Wednesday, june 7
  • virtual

LGBTQ+ leaders enter the biotech chat

Leaders across biotech are trying to move the needle on LGBTQ+ rights. In the midst of calls for diversity in clinical trials, board rooms and management teams, they face a cash crunch in the industry and anti-LGBTQ bills. From the lab to the C-suite, Endpoints News sits down with some of these executives, entrepreneurs and researchers to discuss what happens from here.

Eliav Barr

Eliav Barr

Head of Global Clinical Development and Chief Medical Officer

Merck
Alaina Kupec

Alaina Kupec

Senior Director, Portfolio Strategy & Analytics

Gilead
Mira Chaurushiya

Mira Chaurushiya

Managing Director

Westlake Village BioPartners
Paul J. Hastings

Paul J. Hastings

President & Chief Executive Officer

Nkarta
Tia Lyles-Williams

Tia Lyles-Williams

Founder & CEO

Goffman Bougard, Inc
Kyle Lanhucik

Kyle LaHucik

Editor

Endpoints News
Wednesday, june 7
  • Virtual

The evolution of clinical trials

From Phase I to Phase III, clinical trials have become more complex, with more purposes and stakeholders. Efficacy endpoints are common from the start. Speed is increasingly critical to make business decisions about moving forward of heading to regulators. And an increasingly open accelerated approval pathway means that it’s imperative to collect more evidence earlier. Our panel of experts will unpack how clinical trial design has evolved in recent years, where it’s going, and what it means for the industry.

Frank S. David

Frank S. David

Managing Director

Pharmagellan
Christine Grause

Christine Grause

VP of Late Development Statistics

Merck
Greg DiRusso

Greg DiRusso

Hematology Development Head

Pfizer
Becker Hewes

Becker Hewes

Chief Medical Officer

Blueprint Medicines
Drew Armstrong

Drew Armstrong

Executive Editor

Endpoints News
Wednesday, june 7
  • Virtual

Forging new biotech ties with China

As China’s impact on drug sciences continues to grow, biopharma companies in the US and Europe have been carefully navigating the landscape of drug development in the world’s second largest pharma market. We’ll talk to some experienced players about ways large and small players can develop a truly global strategy — and everything that entails.

Weiguo Su

Weiguo Su

Executive Director, Chief Executive Officer & Chief Scientific Officer

HUTCHMED
Min Li

Min Li

Founder & CEO

SciNeuro Pharmaceuticals
Kerry Blanchard

Kerry Blanchard

Co-founder, Chairman & CEO

Perpetual Medicines
Andy Liu

Andy Liu

Head of China

Novotech
Hongbo Lu

Hongbo Lu

Managing Partner

Vivo Capital
John Carroll

John Carroll

Editor & Founder

Endpoints News

No cost to register, subject to confirmation. By registering for this event, you accept that you may receive direct communication from the sponsor(s). If you are experiencing problems with your registration, please contact our support team.